These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 25248470)

  • 1. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
    Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
    Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
    Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
    Zapatero A; Martin De Vidales C; Arellano R; Ibañez Y; Bocardo G; Perez M; Rabadan M; García Vicente F; Cruz Conde JA; Olivier C
    Urology; 2012 Nov; 80(5):1056-62. PubMed ID: 22999456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma.
    Aboziada MA; Hamza HM; Abdlrahem AM
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):167-74. PubMed ID: 21057568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cho SW; Lim SH; Kwon GY; Kim CK; Park W; Pyo H; Chung JH; Song W; Sung HH; Jeong BC; Park SH
    Cancer Res Treat; 2024 Jul; 56(3):893-897. PubMed ID: 38374699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience.
    Tunio MA; Hashmi A; Qayyum A; Mohsin R; Zaeem A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e457-62. PubMed ID: 21945107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
    Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
    J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder sparing surgery in high-grade bladder cancer.
    Yakovlev PG; Klyushin DA; Vereshchako RI
    Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer.
    Turgeon GA; Souhami L; Cury FL; Faria SL; Duclos M; Sturgeon J; Kassouf W
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):326-31. PubMed ID: 24411604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
    Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
    Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
    Khosravi-Shahi P; Cabezón-Gutiérrez L
    Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
    Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
    Feng YH; Shen KH; Huang KH; Tzeng WS; Li CF; Lin KL
    Clin Genitourin Cancer; 2016 Feb; 14(1):e67-74. PubMed ID: 26428609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.